相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- LakeShore Biopharma has received regulatory approval for a novel packaging solution for its YSJA™ rabies vaccine featuring needle-free reconstitution technology, with nationwide distribution in China beginning within weeks. - The innovative system addresses critical safety challenges by utilizing closed sterile connection technology to reduce contamination risks, prevent needlestick injuries to healthcare workers, and minimize patient discomfort during administration. - This launch represents the first commercial application of advanced liquid transfer device technology in China's rabies vaccine market, establishing LakeShore as an early innovator in vaccine delivery safety within the country.
• LakeShore Biopharma has initiated the BLA submission to Pakistan's DRAP for its PIKA Rabies Vaccine, targeting post-exposure prophylaxis. • Phase III trial data supports the application, demonstrating the vaccine's ability to accelerate protection against rabies. • The trial met primary immunogenicity endpoints, showing a rapid seroconversion rate and a tolerable safety profile. • PIKA Rabies Vaccine utilizes LakeShore’s PIKA adjuvant technology to elicit a stronger, faster immune response.
• LakeShore Biopharma has initiated a Biologics License Application (BLA) with Pakistan's Drug Regulatory Authority for its PIKA rabies vaccine. • Phase 3 trial data demonstrated the vaccine's ability to provide accelerated protection in a one-week regimen, compared to the standard three- or four-week regimens. • The trial, involving 4,500 participants, showed superior immunogenicity and safety, addressing a critical need in a country with high rabies prevalence. • PIKA rabies vaccine utilizes proprietary PIKA adjuvant technology to produce a robust immune response, and has received FDA orphan drug designation.
- LakeShore Biopharma's YSJA rabies vaccine will be evaluated in a Phase III trial in China using simplified four-dose regimens. - The trial aims to compare the immunogenicity and safety of the Zagreb (2-1-1) and Modified Essen (1-1-1-1) regimens against the standard Essen regimen (1-1-1-1-1). - Simplified schedules could improve patient adherence, reduce healthcare burden, and enhance the vaccine's competitiveness in the rabies vaccine market. - Rabies, with a near 100% fatality rate if untreated, claims approximately 59,000 lives annually, highlighting the need for improved vaccination strategies.
- LakeShore Biopharma's YSJA rabies vaccine has received approval for a Phase III clinical trial in China to assess a simplified four-dose regimen. - The trial will evaluate the immunogenicity and safety of two four-dose schedules against the standard five-dose Essen regimen. - This simplified schedule aims to improve patient adherence, reduce healthcare burden, and enhance the vaccine's market competitiveness. - The study, starting in December 2024, is a randomized, double-blind, controlled trial conducted at a single center.
- LakeShore Biopharma received approval for a Phase III clinical trial in China to assess simplified four-dose regimens of its YSJA rabies vaccine. - The trial will compare two four-dose regimens (Zagreb and Modified Essen) against the standard five-dose Essen regimen for immunogenicity and safety. - The simplified regimens aim to improve patient adherence, reduce healthcare burden, and enhance the vaccine's competitiveness in the rabies vaccine market. - The YSJA rabies vaccine has already been administered in over 100 million doses, marking it as a key player in rabies prevention efforts.
- LakeShore Biopharma's YSJA rabies vaccine receives approval for a Phase III clinical trial in China to assess simplified four-dose regimens. - The trial will compare two four-dose regimens (Zagreb and Modified Essen) against the standard five-dose Essen regimen for immunogenicity and safety. - The simplified regimens aim to improve patient adherence, reduce healthcare burden, and enhance the vaccine's utility in rabies prevention. - Rabies is almost 100% fatal without treatment, causing approximately 59,000 deaths annually, with 40% occurring in children under 15.
- LakeShore Biopharma received approval from China's NMPA for a Phase III trial of its YSJA rabies vaccine, aiming to simplify the immunization schedule. - The trial will assess the immunogenicity and safety of two four-dose regimens (Zagreb and Modified Essen) compared to the standard five-dose Essen regimen. - Simplified regimens could improve patient adherence, reduce healthcare burden, and enhance the vaccine's competitiveness in the rabies vaccine market. - The YSJA rabies vaccine has already sold over 100 million doses and is a key product in preventing rabies-related deaths and disabilities.
- LakeShore Biopharma's YSJA rabies vaccine has received approval from China's NMPA for a Phase III clinical trial exploring a simplified four-dose regimen. - The trial will assess the immunogenicity and safety of two four-dose schedules compared to the standard Essen regimen, potentially improving patient adherence. - This simplified schedule aims to reduce physician workload, minimize hospital visits, and lower the financial burden on patients while maintaining comparable immunogenicity. - The Phase III trial is set to commence in December 2024 and will be a single-center, randomized, double-blind, controlled study.
